- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00135434
Effect of HIV Protease Inhibitor Drugs on Glucose and Insulin Metabolism
April 7, 2011 updated by: Bristol-Myers Squibb
This study examined the effects of two commonly prescribed HIV drugs on the way the body metabolizes glucose, insulin and fat.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment
25
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New Jersey
-
Hamilton, New Jersey, United States, 08690
- Clinical Pharmacology Unit, Bristol-Myers Squibb Company
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy volunteers
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Insulin sensitivity by euglycemic hyperinsulinemic clamp method
|
Secondary Outcome Measures
Outcome Measure |
---|
Insulin sensitivity by oral glucose tolerance
|
Lipids and lipoproteins
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2004
Primary Completion (Actual)
June 1, 2005
Study Completion (Actual)
June 1, 2005
Study Registration Dates
First Submitted
August 25, 2005
First Submitted That Met QC Criteria
August 25, 2005
First Posted (Estimate)
August 26, 2005
Study Record Updates
Last Update Posted (Estimate)
April 8, 2011
Last Update Submitted That Met QC Criteria
April 7, 2011
Last Verified
November 1, 2009
More Information
Terms related to this study
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- HIV Infections
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Protease Inhibitors
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- HIV Protease Inhibitors
- Viral Protease Inhibitors
- Ritonavir
- Lopinavir
- Atazanavir Sulfate
Other Study ID Numbers
- AI424-130
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on Atazanavir/Ritonavir/Lopinavir/ritonavir
-
Bristol-Myers SquibbCompleted
-
Bristol-Myers SquibbCompletedHIVArgentina, France, Taiwan, Thailand, United States, Chile, Spain, Dominican Republic, Guatemala, Peru, Puerto Rico, Singapore, Russian Federation, Italy, Mexico, Colombia, South Africa, Brazil, Hungary, Malaysia, Portugal, Canada, I... and more
-
Massachusetts General HospitalBristol-Myers SquibbCompleted
-
ViiV HealthcarePfizerCompletedHuman Immunodeficiency Virus-1United States, Spain, Germany
-
Indiana UniversityNational Heart, Lung, and Blood Institute (NHLBI)CompletedEndothelial DysfunctionUnited States
-
Bristol-Myers SquibbCompletedHIV InfectionsUnited States, Canada, Argentina, Belgium, Chile, Mexico, Spain, Italy, Australia, Brazil, France, Puerto Rico, United Kingdom, Netherlands, Peru
-
Drugs for Neglected DiseasesUniversity of Cape Town; Medecins Sans Frontieres, Netherlands; UBS Optimus Foundation and other collaboratorsCompletedAcquired Immunodeficiency Syndrome | TuberculosisSouth Africa
-
Bristol-Myers SquibbCompleted
-
McGill University Health Centre/Research Institute...Merck Sharp & Dohme LLC; CIHR Canadian HIV Trials NetworkCompletedHepatitis C | HIV | Liver FibrosisCanada
-
University of LiverpoolJanssen Pharmaceutica; Yaounde Central Hospital; Chantal Biya International Reference...Completed